peptide-information

Purity is the single variable that lets a synthetic peptide behave predictably in an experiment. This article reviews how researchers remove the by-products of chemical synthesis, why certain impurities are difficult to separate, and how the final purity of a research peptide is measured rather than assumed.

Why purity defines a research peptide

Advances in solid-phase synthesis have made custom peptides available on a scale that would have been unthinkable a few decades ago, and that abundance has made purification more central, not less. Under the definition used by the United States Food and Drug Administration, a chain of forty or fewer amino acids is classed as a peptide, while longer chains are treated as proteins.¹ Most research peptides sit well inside that range, yet even short sequences arrive from the synthesizer as a mixture: the desired molecule accompanied by structurally related contaminants.

Peptides are conformationally complex, and that complexity makes the crystallization strategies that work for many small organic compounds largely ineffective. Instead, purification leans almost entirely on chromatography, and reversed-phase high-performance liquid chromatography (RP-HPLC) has long been the default method for isolating synthetic peptides.² The practical aim is to isolate the target sequence from a crowded mixture with enough resolution and recovery to be reproducible, because a contaminant that co-elutes with the target can quietly distort any downstream measurement built on top of it.

Where impurities come from during synthesis

Solid-phase peptide synthesis (SPPS), the framework introduced by Merrifield and refined across more than a century of peptide chemistry, builds a chain one residue at a time on an insoluble resin.³⁴ Each cycle couples a protected amino acid, then removes the temporary protecting group before the next coupling. The chemistry is efficient but never perfect, and the small failure rate at every step accumulates into a defined family of by-products.

The most common are deletion sequences, where a coupling step fails and the chain continues one residue short, and truncated peptides, where elongation stops entirely.⁵ Because these differ from the target by only one or a few residues, they are chemically similar to it and correspondingly hard to separate. Regulatory reviews of synthetic peptide products describe the same landscape from the quality-control side: amino-acid insertions, deletions and side-chain modifications are recognised impurity classes that manufacturers are expected to characterise and control.⁶

Further contaminants arise from the chemistry itself. Hydrolysis of labile amide bonds, diastereomers formed by racemisation of a chiral centre during coupling, aspartimide formation at sensitive aspartate residues, and by-products generated during the final deprotection and cleavage step all add to the mixture.⁷ Sequences containing cysteine can also form unwanted disulfide-linked dimers and higher polymeric species when the peptide is meant to cyclise. Each class behaves differently in a separation, so recognising which impurities a given sequence is prone to generate is the first step in choosing how to purify it.

Purification strategy: capture then polish

A good purification strategy is as short as possible: reach the required purity in the fewest steps, because every additional step costs yield. In practice, two complementary processes run in sequence often outperform a single long one, particularly when each operates on a different chromatographic principle.⁸

The first stage is usually a capture step that removes the bulk of the impurities. Many of these come from the final cleavage step — scavenger reagents and small, uncharged, low-molecular-weight fragments — and a single reversed-phase pass can eliminate most of them.⁸ When higher purity is needed, a second polishing step follows. Its power comes from orthogonality: if capture separated molecules by hydrophobicity, a polishing step that separates by charge can resolve contaminants the first step could not. Ion-exchange chromatography used ahead of reversed-phase chromatography is a classic pairing that can yield a very high-purity final product.⁹ Even the closely related deletion sequences can be pushed apart from the target when a shallow, carefully designed elution gradient is applied to a reversed-phase separation.⁵

The chromatographic toolkit

Every chromatographic mode exploits a different physical property. Understanding what each one separates by explains why they are combined, and why no single method is universally best.

Affinity chromatography (AC)

Affinity chromatography isolates a molecule using a specific, reversible interaction with a ligand immobilised on the column matrix. The target binds the ligand, unbound material is washed away, and conditions are then changed to release the captured molecule — either specifically, by introducing a competing ligand, or non-specifically, by altering pH, polarity or ionic strength.¹⁰ Because the recognition is molecular rather than bulk-physical, affinity methods can offer both high selectivity and high capacity, though they require a ligand tailored to the target.

Ion-exchange chromatography (IEX)

Ion exchange separates molecules by net charge. A peptide of a given charge binds to a stationary phase carrying the opposite charge; bound species are then eluted differentially by raising salt concentration (commonly sodium chloride) or shifting pH.⁶⁹ The target concentrates on the column during binding and is collected as it elutes, which makes IEX a high-resolution, high-capacity option and a natural partner for a later hydrophobicity-based step.

Hydrophobic interaction chromatography (HIC)

HIC works on surface hydrophobicity. Under a high-ionic-strength buffer, hydrophobic patches on the peptide interact reversibly with a mildly hydrophobic stationary phase; lowering the salt concentration — often on a decreasing ammonium sulfate gradient — releases bound species in order of hydrophobicity.⁹ Because it uses high salt to promote binding, HIC dovetails neatly after a salt-based elution such as IEX, and it tends to be gentler than reversed-phase methods.

Gel filtration / size-exclusion chromatography (SEC)

Size-exclusion chromatography separates purely by molecular size: larger molecules pass around the porous matrix and elute first, smaller ones are retained longer.¹¹ SEC is limited to small sample volumes and modest loading, but it offers good resolution and is especially useful for removing aggregates, dimers or polymeric by-products whose size differs clearly from the monomeric target.

Reversed-phase chromatography (RPC)

Reversed-phase chromatography is the workhorse of peptide purification and delivers very high resolution. It relies on the reversible interaction between the peptide and a hydrophobic stationary phase; because that binding is strong, elution requires an organic solvent — typically an increasing gradient of acetonitrile.² An acidic ion-pairing additive such as trifluoroacetic acid is usually included, and the choice and concentration of that additive markedly change selectivity: more hydrophobic counter-ions can even coax charge-based separation out of a nominally hydrophobicity-based method.¹² RPC excels as a polishing step and for analytical work such as peptide mapping, but the organic solvents that make it powerful can denature folded peptides, so it is a poor choice when a defined tertiary structure must be recovered intact.

Reading a purity report: HPLC and mass spectrometry

Purification and analysis are two sides of the same problem: a peptide is only as pure as the method used to check it can prove. Characterisation of synthetic peptides typically combines reversed-phase HPLC with ultraviolet detection to quantify the main peak, and high-resolution mass spectrometry to confirm identity and flag mass-shifted impurities.⁶ The percentage figure quoted on a certificate of analysis is essentially the area of the main HPLC peak relative to everything else the detector sees.

That framing exposes a subtle limitation. Some impurities — notably diastereomers and other isomers — share the exact mass of the target, so mass spectrometry alone cannot distinguish them; they must be resolved chromatographically or they hide inside the main peak.¹³ This is why analysts increasingly turn to orthogonal or two-dimensional separations to test whether a single HPLC peak is genuinely one compound. A high number on a report is therefore only as trustworthy as the method's ability to separate closely related species in the first place. When a research peptide such as BPC-157 or a longer, more complex sequence like semaglutide is described as high-purity, the meaningful question is which analytical method produced that figure.

Why acceptable purity thresholds vary

There is no universal purity requirement; the acceptable minimum depends entirely on how the peptide will be used. In vitro studies generally demand a high standard — often greater than 95% — because a co-eluting contaminant can confound the readout of a sensitive assay. Other applications tolerate more. Using peptides as an ELISA standard for antibody titre measurement, for example, may accept purity around 70%, because the assay is comparatively forgiving of minor by-products.¹⁴

The consequence is that "pure enough" is a decision made against a specific experimental purpose, not a fixed target. Matching purity to application avoids both under-purified material that undermines an experiment and over-purified material that wastes yield and cost. This is also why deletion and truncation impurities receive particular scrutiny in regulated settings: even at low levels, structurally related by-products can behave differently from the intended sequence, which is why guidance for synthetic peptide products asks manufacturers to keep such impurities characterised and controlled.⁶

Process control and documentation

Reproducible purity is a process outcome, not a single event. The physical hardware of a purification system — buffer and solvent delivery, fractionation, detection and data capture — matters, but the column is the heart of the operation, and choices such as its material and compression mode influence the result.⁸ Purification also sits near the end of the synthesis route, so it has an outsized effect on the quality of the finished peptide.

For that reason, disciplined manufacturers treat purification under documented, reproducible procedures modelled on good manufacturing practice: test methods and specifications defined in advance, critical parameters identified with limits, and analytical steps recorded. Parameters that are typically fixed and monitored include column loading, flow rate, column performance and cleaning, elution-buffer composition, in-process hold times and how fractions are pooled.⁶ Qovigen supplies research peptides accompanied by batch-specific analytical documentation so that a laboratory can see the method and the measured purity rather than take a claim on trust.

What a purity figure does not tell you

Purity is a chemical statement about composition. It says how much of a sample is the intended sequence and how much is something else. It does not describe how a peptide behaves in a biological system, nor does it certify anything about safety or physiological effect. A 99% pure research peptide is 99% pure — no more, no less.

It is also worth stating plainly that most of the peptides discussed in this context are not approved by the FDA or comparable agencies for human or veterinary use. They are laboratory materials, and the purification science described here exists to make experimental results reliable, not to imply any therapeutic property. Purity and approval are entirely separate questions, and a clean chromatogram answers only the first.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.